With support from INOVAIT’s Pilot Fund, PulseMedica is addressing critical gaps in vitreoretinal care with a first-of-its-kind diagnostic and treatment platform—initially focused on symptomatic eye floaters. The system integrates high-resolution 3D imaging, real-time tracking, and machine learning algorithms to detect and classify floaters at earlier stages, enabling more accurate diagnoses and timely clinical intervention. PulseMedica’s platform overcomes a long-standing challenge in ophthalmology: the inability to non-invasively visualize and precisely treat pathology in the posterior segment of the eye. By leveraging femtosecond laser technology, PulseMedica’s device enables real-time, image-guided treatment that destroys floaters directly within the vitreous—eliminating the need for invasive surgery. This non-invasive, office-based approach represents a major advancement for both patients and clinicians. PulseMedica’s goal is for ophthalmologists to have access to a safe, effective, and scalable solution for floater treatment—bringing meaningful relief to millions of patients who currently have no viable therapeutic options. Building on the success of its Pilot Fund project, PulseMedica’s Focus Fund project supported efforts to advance the development of next-generation prototypes that integrate comprehensive 3D imaging, automated floater detection, and laser-based treatment delivery into a single unified platform system. These systems will be evaluated in first-in-human clinical trials for floater treatment, representing a pivotal milestone in the path toward commercial application. By reducing the burden of care and offering a scalable solution to a highly prevalent condition, PulseMedica is positioned to reshape the standard of care in ophthalmology—starting with the $35B U.S. market opportunity for symptomatic floaters.